$ANAB
AnaptysBio Inc Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000137005317000005 Filed on May 12, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$0.00	$4.866M
YoY Change	-100.0%	18.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.050M	$1.220M
YoY Change	68.03%	79.41%
% of Gross Profit
Research & Development	$7.935M	$4.786M
YoY Change	65.8%	56.41%
% of Gross Profit
Depreciation & Amortization	$39.00K	$57.00K
YoY Change	-31.58%	-18.57%
% of Gross Profit
Operating Expenses	$9.988M	$6.005M
YoY Change	66.33%	60.13%
Operating Profit	-$9.988M	-$1.139M
YoY Change	776.91%
Interest Expense	$428.0K	$115.0K
YoY Change	272.17%	-204.55%
% of Operating Profit
Other Income/Expense, Net	-$1.447M	$251.0K
YoY Change	-676.49%	-141.15%
Pretax Income	-$11.44M	-$890.0K
YoY Change	1185.39%	134.21%
Income Tax
% Of Pretax Income
Net Earnings	-$11.44M	-$888.0K
YoY Change	1187.73%	133.68%
Net Earnings / Revenue		-18.25%
Basic Earnings Per Share	-$0.75	-$0.34
Diluted Earnings Per Share	-$0.75	-$0.34
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.5M	$49.30M
YoY Change	109.93%	151.53%
Cash & Equivalents	$96.75M	$49.30M
Short-Term Investments	$6.742M
Other Short-Term Assets	$1.700M	$900.0K
YoY Change	88.89%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$110.2M	$51.40M
YoY Change	114.31%	132.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$569.0K	$500.0K
YoY Change	13.8%	-16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$20.30M
YoY Change
Other Assets	$100.0K	$2.800M
YoY Change	-96.43%	2700.0%
Total Long-Term Assets	$20.96M	$3.300M
YoY Change	535.03%	371.43%
TOTAL ASSETS
Total Short-Term Assets	$110.2M	$51.40M
Total Long-Term Assets	$20.96M	$3.300M
Total Assets	$131.1M	$54.70M
YoY Change	139.69%	139.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.546M	$700.0K
YoY Change	263.71%	0.0%
Accrued Expenses	$4.330M	$2.800M
YoY Change	54.64%	300.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.300M	$400.0K
YoY Change	225.0%	33.33%
Total Short-Term Liabilities	$8.126M	$7.100M
YoY Change	14.45%	-37.17%
LONG-TERM LIABILITIES
Long-Term Debt	$12.70M	$4.500M
YoY Change	182.22%	-2.17%
Other Long-Term Liabilities	$200.0K	$1.300M
YoY Change	-84.62%	8.33%
Total Long-Term Liabilities	$12.90M	$5.800M
YoY Change	122.41%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.126M	$7.100M
Total Long-Term Liabilities	$12.90M	$5.800M
Total Liabilities	$21.00M	$12.90M
YoY Change	62.79%	-24.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.40M
YoY Change
Common Stock	$20.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$110.1M	$41.80M
YoY Change
Total Liabilities & Shareholders Equity	$131.1M	$54.70M
YoY Change	139.69%	139.91%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$11.44M	-$888.0K
YoY Change	1187.73%	133.68%
Depreciation, Depletion And Amortization	$39.00K	$57.00K
YoY Change	-31.58%	-18.57%
Cash From Operating Activities	-$8.097M	-$2.056M
YoY Change	293.82%	-19.06%
INVESTING ACTIVITIES
Capital Expenditures	$85.00K	$35.00K
YoY Change	142.86%	-143.75%
Acquisitions
YoY Change
Other Investing Activities	-$27.00M
YoY Change
Cash From Investing Activities	-$27.09M	-$35.00K
YoY Change	77285.71%	-56.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$80.21M	$1.000K
YoY Change	-8021400.0%	-97.5%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$80.70M	-$275.0K
YoY Change	-29446.91%	-787.5%
NET CHANGE
Cash From Operating Activities	-$8.097M	-$2.056M
Cash From Investing Activities	-$27.09M	-$35.00K
Cash From Financing Activities	$80.70M	-$275.0K
Net Change In Cash	$45.52M	-$2.366M
YoY Change	-2024.01%	-8.29%
FREE CASH FLOW
Cash From Operating Activities	-$8.097M	-$2.056M
Capital Expenditures	$85.00K	$35.00K
Free Cash Flow	-$8.182M	-$2.091M
YoY Change	291.3%	-15.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2016Q4	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	2084000	USD
CY2017Q1	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	3423000	USD
CY2016Q1	anab	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2366000	USD
CY2017Q1	anab	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	45522000	USD
CY2015Q4	anab	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	51744000	USD
CY2016Q1	anab	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	49378000	USD
CY2016Q4	anab	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	51292000	USD
CY2017Q1	anab	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	96814000	USD
CY2017Q1	anab	Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions	16700000	USD
CY2017Q1	anab	Number Of Financial Institutions Utilized For Diversification Of Funds NumberOfFinancialInstitutionsUtilizedForDiversificationOfFunds	3	bank
CY2016Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	4118000	USD
CY2017Q1	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	4965000	USD
CY2016Q1	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	322000	USD
CY2017Q1	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	866000	USD
CY2016Q1	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	260000	USD
CY2017Q1	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	1290000	USD
CY2016Q1	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	0	USD
CY2017Q1	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	4607000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20269273	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO INC
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2278000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2546000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3429000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4330000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	296000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	137000	USD
CY2016Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	154000	USD
CY2017Q1	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	161000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3798000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3837000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16672000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176507000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13959000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2327000	shares
CY2016Q4	us-gaap	Assets Assets	62180000	USD
CY2017Q1	us-gaap	Assets Assets	131111000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	58208000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	110155000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28692000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28679000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	6742000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	20327000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	52000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51232000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96754000	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	198009	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4125815	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	17214000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2651000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20249000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20249295	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2651000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20249295	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20249000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-888000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11448000	USD
CY2016Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3441000	USD
CY2017Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	57000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3241000	USD
CY2017Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	973000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	659000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-379000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1366000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1219000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2053000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1093000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	682000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-139000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2016Q1	us-gaap	Increase Decrease In Contract Receivables Net IncreaseDecreaseInContractReceivablesNet	-35000	USD
CY2017Q1	us-gaap	Increase Decrease In Contract Receivables Net IncreaseDecreaseInContractReceivablesNet	-1225000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	323000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2017Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	847000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	316000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	143000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	115000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	428000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	87000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	278000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62180000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131111000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5708000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8126000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-275000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80704000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27085000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2056000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8097000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-888000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11435000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	251000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1447000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1250000	USD
CY2016Q4	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	13809000	USD
CY2017Q1	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	12709000	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	6005000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	9988000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1139000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9988000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	76000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	111000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-22000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-150000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	347000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	283000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	399000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	27000000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	85000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	11520698	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1633000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1694000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	80213000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	355000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	535000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4269000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4406000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	471000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	569000	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1225000	USD
CY2017Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	0	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4786000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7935000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54923000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66400000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66399000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	4866000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1204923	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	13823	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.15
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	934141	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	47184000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1879428	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2722883	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.42
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.63
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.13
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M25D
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	76863	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-38248000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	110115000	USD
CY2017Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1429
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2629000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15295000	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and certain investments in money market funds, agency securities, commercial paper and U.S. treasury securities. Bank deposits are diversified between </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> financial institutions and these deposits may exceed insured limits. We are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents and issuers of investments that are recorded on our consolidated balance sheets. We mitigate our risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits our exposure.</font></div></div>
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of the Business </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates using our proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. We currently generate revenue from our collaborative research and development arrangements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities, and at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, have an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$66.4 million</font><font style="font-family:inherit;font-size:10pt;">. Through </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, all of our financial support has been provided primarily from the sale of our common and preferred stock, proceeds from the issuance of convertible debt and funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering and Related Transactions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">On January 31, 2017, we completed an initial public offering, or IPO, selling </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5,750,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> shares of common stock at </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$15.00</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per share. Proceeds from our initial public offering net of underwriting discounts and commissions were </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$80.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In addition, each of the following occurred in connection with the completion of the IPO on January 31, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of all outstanding shares of convertible preferred stock into </font><font style="font-family:inherit;font-size:10pt;">11,520,698</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock into warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and the resultant reclassification of the warrant liability to additional paid-in capital.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, we amended and restated our certificate of incorporation to effect a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split of every outstanding share of our preferred and common stock. The financial statements and accompanying footnotes have been retroactively restated to reflect the reverse stock split.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.</font></div></div>

Files In Submission

Name	View Source	Status
0001370053-17-000005-index-headers.html	Edgar Link	pending
0001370053-17-000005-index.html	Edgar Link	pending
0001370053-17-000005.txt	Edgar Link	pending
0001370053-17-000005-xbrl.zip	Edgar Link	pending
anab-033117x10q.htm	Edgar Link	pending
anab-033117x10qxexx31.htm	Edgar Link	pending
anab-033117x10qxexx311.htm	Edgar Link	pending
anab-033117x10qxexx312.htm	Edgar Link	pending
anab-033117x10qxexx321.htm	Edgar Link	pending
anab-033117x10qxexx322.htm	Edgar Link	pending
anab-20170331.xml	Edgar Link	completed
anab-20170331.xsd	Edgar Link	pending
anab-20170331_cal.xml	Edgar Link	unprocessable
anab-20170331_def.xml	Edgar Link	unprocessable
anab-20170331_lab.xml	Edgar Link	unprocessable
anab-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
AnaptysBio Inc Stock $anab

2017 Q1 Form 10-Q Financial Statement

#000137005317000005 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB AnaptysBio Inc Stock $anab

2017 Q1 Form 10-Q Financial Statement

#000137005317000005 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
AnaptysBio Inc Stock $anab